What is Dendreon?
Founded in 1992 and headquartered in Seal Beach, California, Dendreon operates at the intersection of immunology and oncology. The company is primarily recognized for its specialized focus on the development and manufacturing of immune-therapeutics designed to treat various forms of cancer. By leveraging sophisticated biological processes, Dendreon aims to provide targeted solutions that enhance patient outcomes. Its market position is defined by a long-standing history of innovation, transitioning from early-stage research to established enterprise-level operations that address critical unmet needs in cancer care.
How much funding has Dendreon raised?
Dendreon has raised a total of $50M across 2 funding rounds:
Stock Offering
$45M
Debt
$5M
Stock Issuance/Offering (2000): $45M, investors not publicly disclosed
Debt (2020): $5M led by PPP
Key Investors in Dendreon
PPP
Public-Private Partnership
Undisclosed Investor
A private participant in the company's historical stock issuance, contributing to the foundational capital structure of the organization.
What's next for Dendreon?
Looking ahead, the infusion of capital from the latest financing round is expected to catalyze Dendreon's operational scaling and clinical expansion. As the company moves deeper into its current lifecycle stage, the focus will likely shift toward optimizing manufacturing efficiencies and expanding the reach of its therapeutic portfolio. By prioritizing strategic growth and maintaining its rigorous standards for immune-therapeutic development, Dendreon is well-positioned to sustain its influence in the biotechnology sector. Future milestones will likely involve the integration of advanced manufacturing technologies and the pursuit of new clinical indications to broaden its therapeutic impact.
See full Dendreon company page
